Benzinga | May 5, 2021 04:20PM EDT

Fate Therapeutics Q1 EPS $(0.48) Misses $(0.43) Estimate, Sales $11.14M Beat $5.90M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.43) by 11.63 percent. This is a 9.09 percent decrease over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $11.14 million which beat the analyst consensus estimate of $5.90 million by 88.85 percent. This is a 343.02 percent increase over sales of $2.52 million the same period last year.